For sufferers with relapsed or refractory a number of myeloma, talquetamab plus teclistamab reveals response in a excessive proportion of sufferers and the next incidence of grade 3 or 4 infections than with both remedy alone, in accordance with a research revealed within the New England Journal of Drugs.
Yael C. Cohen, M.D., from the Tel Aviv Sourasky Medical Heart in Israel, and colleagues carried out a part 1b-2 research of talquetamab plus teclistamab in sufferers with relapsed or refractory a number of myeloma. 5 dose ranges had been investigated in a dose-escalation research in part 1. The really useful part 2 routine was talquetamab at a dose of 0.8 mg/kg physique weight plus teclistamab at a dose of three.0 mg/kg each different week. The first goal of the research was to guage hostile occasions and dose-limiting poisonous results.
Ninety-four sufferers acquired remedy; 44 used the really useful part 2 routine. Sufferers had been adopted for a median of 20.3 months. The researchers discovered that three sufferers had dose-limiting poisonous results (together with one with grade 4 thrombocytopenia, who acquired the really useful part 2 routine). The commonest hostile occasions throughout all dose ranges had been cytokine launch syndrome, neutropenia, style modifications, and nonrash pores and skin occasions.
Ninety-six p.c of sufferers had grade 3 or 4 hostile occasions, most frequently hematologic occasions. Sixty-four p.c of sufferers had grade 3 or 4 infections. A response occurred in 80% of the sufferers with the really useful part 2 routine and in 78% throughout all dose ranges. The chance of sufferers persevering with in response at 18 months was 86 and 77% with the really useful part 2 routine and throughout all dose ranges, respectively.
“On the basis of these results, this dual-targeting, off-the-shelf combination therapy warrants further investigation in patients with relapsed or refractory multiple myeloma,” the authors write.
Extra info:
Yael C. Cohen et al, Talquetamab plus Teclistamab in Relapsed or Refractory A number of Myeloma, New England Journal of Drugs (2025). DOI: 10.1056/NEJMoa2406536
2025 HealthDay. All rights reserved.
Quotation:
Talquetamab plus teclistamab reveals promise in a number of myeloma (2025, January 9)
retrieved 10 January 2025
from https://medicalxpress.com/information/2025-01-talquetamab-teclistamab-multiple-myeloma.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
